Isocitrate dehydrogenase (IDH) mutations are indicative of favorable outcomes in all glioma patients [3], whereas telomerase reverse transcriptase promoter (TERTp) mutations are associated with poor prognosis in patients with glioblastoma (GBM), a grade IV glioma [4]. The gene discussed is IDH1; the disease is central nervous system cancer.